Effects of upadacitinib on lipid profiles and their relationship with inflammation in patients with inflammatory bowel disease: a real-world longitudinal cohort study
Inflammatory Bowel Diseases · 05.11.2026
DOI: 10.1093/ibd/izag241 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 05.11.2026. Verfasst von Shengduo He und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Peking University First Hospital, Beijing, China. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Upadacitinib (UPA), a selective Janus kinase 1 inhibitor, is approved for moderate-to-severe inflammatory bowel disease (IBD). JAK inhibitors affect lipid metabolism, but longitudinal real-world data on lipid changes during UPA therapy, and their relation to inflammatory activity, are scarce.
Methods
In this single-center retrospective cohort study, patients with ulcerative colitis or Crohn’s disease treated with upadacitinib were followed for up to 2 years. Serial fasting lipid profiles and inflammatory markers (fecal calprotectin, C-reactive protein [CRP], high-sensitivity CRP) were collected at baseline, end of induction (weeks 8-12), 1 year, and 2 years. Lipid trajectories were analyzed with linear mixed-effects models; paired changes were compared with paired t-tests.
Results
Among 159 patients (mean age 43.3 ± 14.0 years; 62.3% male), total cholesterol (TC) rose from 4.19 ± 0.87 mmol/L at baseline to 4.92, 5.03, and 5.21 mmol/L at the end of induction, 1 year, and 2 years (mixed-effects estimates +0.70 to +0.90; all P < .001). Low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) rose in parallel, and the LDL-C/HDL-C ratio did not increase. CRP reductions correlated with lipid rises (Spearman rho = −0.45 to −0.47; all P ≤ .02). No cardiovascular death, myocardial infarction, or stroke occurred (0/159); one venous thromboembolism and 3 hypertension cases were recorded.
Conclusions
In patients with IBD treated with UPA, TC and LDL-C rose modestly alongside the resolution of inflammation; HDL-C improved and the LDL-C/HDL-C ratio did not increase. Lipid monitoring and individualized cardiovascular risk assessment are warranted during UPA therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Peking University First Hospital, Beijing, China.
ORCID-Profile: Shengduo He, Wei Zhang, Yu Tian
Zitieren
APA
He, S., Zhang, W., Tian, Y., Ge, C., Teng, G., Li, J., Wang, H., Dai, Y., & Tian, Y. (2026). Effects of upadacitinib on lipid profiles and their relationship with inflammation in patients with inflammatory bowel disease: a real-world longitudinal cohort study. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izag241
Vancouver
He S, Zhang W, Tian Y, Ge C, Teng G, Li J, et al. Effects of upadacitinib on lipid profiles and their relationship with inflammation in patients with inflammatory bowel disease: a real-world longitudinal cohort study. Inflammatory Bowel Diseases. 2026. doi:10.1093/ibd/izag241
BibTeX
@article{He2026,
author = {He, Shengduo and Zhang, Wei and Tian, Yuling and Ge, Chaoyi and Teng, Guigen and Li, Junxia and Wang, Huahong and Dai, Yun and Tian, Yu},
title = {Effects of upadacitinib on lipid profiles and their relationship with inflammation in patients with inflammatory bowel disease: a real-world longitudinal cohort study},
journal = {Inflammatory Bowel Diseases},
year = {2026},
doi = {10.1093/ibd/izag241}
}
EUVIMED